A Phase I Clinical Trial Evaluating the Safety and Dosing of Relugolix with Novel Hormonal Therapy for the Treatment of Advanced Prostate Cancer

BACKGROUND: Androgen deprivation therapy (ADT), a cornerstone of prostate cancer treatment, is commonly co-prescribed as combination therapy. OBJECTIVE: To better understand the safety and tolerability profile of relugolix, an oral non-peptide gonadotropin-releasing hormone (GnRH) receptor antagonis...

Descripción completa

Detalles Bibliográficos
Autores principales: De La Cerda, Jose, Dunshee, Curtis, Gervasi, Lawrence, Sieber, Paul, Belkoff, Laurence, Tutrone, Ronald, Lu, Sophia, Gatoulis, Sergio C., Brown, Bruce, Migoya, Elizabeth, Shore, Neal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10191952/
https://www.ncbi.nlm.nih.gov/pubmed/37060432
http://dx.doi.org/10.1007/s11523-023-00967-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10191952/
https://www.ncbi.nlm.nih.gov/pubmed/37060432
http://dx.doi.org/10.1007/s11523-023-00967-5

Ejemplares similares